BCYC Overview

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is24.00 USD with a low forecast of 24.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bicycle Therapeutics PLC revenue for the last quarter amounts to 47.95M USD, increased 1193.28

Bicycle Therapeutics PLC. EPS for the last quarter amounts to -0.29 USD, decreased -61.33

Bicycle Therapeutics PLC (BCYC) has 288 emplpoyees as of April 16 2026.

Today BCYC has the market capitalization of 368.05M USD.